Arbutus Biopharma Corporation (NASDAQ:ABUS) shares traded -2.51% lower at $2.33 on Wall Street last session.
In accordance with the data, 5 analysts cover Arbutus Biopharma Corporation (NASDAQ:ABUS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.00, we find $6.00. Given the previous closing price of $2.39, this indicates a potential upside of 151.05 percent. ABUS stock price is now -5.87% away from the 50-day moving average and -5.88% away from the 200-day moving average. The market capitalization of the company currently stands at $367.63M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 1 analysts and a buy by 4. Brokers who have rated the stock have averaged $5.40 as their price target over the next twelve months.
With the price target maintained at $5, Jefferies recently Upgraded its rating from Hold to Buy for Arbutus Biopharma Corporation (NASDAQ: ABUS). On February 25, 2021, Jefferies recently initiated its ‘Hold’ rating on the stock quoting a target price of $5, while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
A total of 25.77% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ABUS stock. A new stake in Arbutus Biopharma Corporation shares was purchased by OASIS MANAGEMENT CO LTD. during the first quarter worth $2,392,000. MARSHALL WACE, LLP invested $916,000 in shares of ABUS during the first quarter. In the first quarter, JACOBS LEVY EQUITY MANAGEMENT, INC acquired a new stake in Arbutus Biopharma Corporation valued at approximately $428,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in ABUS for approximately $211,000. MAN GROUP PLC purchased a new stake in ABUS valued at around $203,000 in the second quarter. In total, there are 159 active investors with 30.00% ownership of the company’s stock.
Arbutus Biopharma Corporation (NASDAQ: ABUS) opened at $2.3900 on Tuesday. During the past 12 months, Arbutus Biopharma Corporation has had a low of $1.85 and a high of $4.16. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.10, and a quick ratio of 5.10. The fifty day moving average price for ABUS is $2.4754 and a two-hundred day moving average price translates $2.4755 for the stock.
The latest earnings results from Arbutus Biopharma Corporation (NASDAQ: ABUS) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.1, beating analysts’ expectations of -$0.13 by 0.03. This compares to -$0.19 EPS in the same period last year. The company reported revenue of $5.95 million for the quarter, compared to $3.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 78.2 percent. For the current quarter, analysts expect ABUS to generate $9.37M in revenue.
Arbutus Biopharma Corporation(ABUS) Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
